Business Description
Faron Pharmaceuticals Oy
ISIN : FI4000153309
Compare
Compare
Traded in other countries / regions
FARON.FinlandFARN.UK4FR.GermanyFPHAF.USA IPO Date
2015-11-17Description
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.52 | |||||
| Equity-to-Asset | -1.48 | |||||
| Debt-to-Equity | -0.87 | |||||
| Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -4.8 | |||||
| 3-Year EPS without NRI Growth Rate | -7.3 | |||||
| 3-Year FCF Growth Rate | 3.2 | |||||
| 3-Year Book Growth Rate | -74.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 92.28 | |||||
| 9-Day RSI | 75.67 | |||||
| 14-Day RSI | 61.33 | |||||
| 6-1 Month Momentum % | -41.18 | |||||
| 12-1 Month Momentum % | -52.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.59 | |||||
| Quick Ratio | 0.59 | |||||
| Cash Ratio | 0.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.6 | |||||
| Shareholder Yield % | -0.33 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -286.54 | |||||
| ROIC % | -398.75 | |||||
| ROC (Joel Greenblatt) % | -10779.13 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -4.57 | |||||
| EV-to-Forward-EBIT | -3.73 | |||||
| EV-to-EBITDA | -4.63 | |||||
| EV-to-Forward-EBITDA | -5.11 | |||||
| EV-to-Forward-Revenue | 768.72 | |||||
| EV-to-FCF | -5.5 | |||||
| Earnings Yield (Greenblatt) % | -21.88 | |||||
| FCF Yield % | -19.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Faron Pharmaceuticals Oy Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | |||
| EPS (TTM) (£) | -0.413 | ||
| Beta | 2.42 | ||
| Volatility % | 67.91 | ||
| 14-Day RSI | 61.33 | ||
| 14-Day ATR (£) | 0.114315 | ||
| 20-Day SMA (£) | 1.309 | ||
| 12-1 Month Momentum % | -52.53 | ||
| 52-Week Range (£) | 1.13 - 3.7 | ||
| Shares Outstanding (Mil) | 72.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Faron Pharmaceuticals Oy Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Faron Pharmaceuticals Oy Stock Events
| Event | Date | Price(£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Faron Pharmaceuticals Oy Frequently Asked Questions
What is Faron Pharmaceuticals Oy(LSE:FARN)'s stock price today?
The current price of LSE:FARN is £1.50. The 52 week high of LSE:FARN is £3.70 and 52 week low is £1.13.
When is next earnings date of Faron Pharmaceuticals Oy(LSE:FARN)?
The next earnings date of Faron Pharmaceuticals Oy(LSE:FARN) is 2024-08-27.
Does Faron Pharmaceuticals Oy(LSE:FARN) pay dividends? If so, how much?
Faron Pharmaceuticals Oy(LSE:FARN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers